Abbott Laboratories (ABT) Receivables (2009 - 2026)

Abbott Laboratories (ABT) has 18 years of Receivables data on file, last reported at $8.2 billion in Q1 2026.

• For the quarter ending Q1 2026, Receivables rose 12.05% year-over-year to $8.2 billion; the trailing twelve-month figure through Mar 2026 stood at $8.2 billion (up 12.05% YoY), and the FY2025 full-year result was $7.9 billion, up 14.5% from the prior year.
• Receivables climbed to $8.2 billion in Q1 2026, from $7.9 billion in the prior quarter.
• In the past five years, Receivables ranged from a high of $8.2 billion in Q1 2026 to a low of $6.0 billion in Q1 2023.
• A 5-year average of $7.0 billion and a median of $6.9 billion in 2024 frame the typical range for Receivables.
• Across the five-year window, Receivables climbed 17.77% in 2022 and declined 16.14% in 2023, its largest moves.
• Tracing ABT's Receivables over 5 years: stood at $6.2 billion in 2022, then grew by 5.58% to $6.6 billion in 2023, then climbed by 5.48% to $6.9 billion in 2024, then gained by 14.5% to $7.9 billion in 2025, then gained by 3.54% to $8.2 billion in 2026.
• Business Quant data shows ABT's Receivables at $8.2 billion in Q1 2026, $7.9 billion in Q4 2025, and $8.1 billion in Q3 2025.